--- title: "Nautilus Biotechnology (NAUT) stock and investor profile" url: "https://aibio.space/companies/nautilus-biotechnology/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Nautilus Biotechnology, Inc. (NASDAQ: NAUT), United States. Listing facts, related biotech companies and news on aibio.space." --- NAUT Nautilus Biotechnology, Inc. NASDAQ · United States # Nautilus Biotechnology (NAUT) news Nautilus Biotechnology, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NAUT, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. ## Latest Nautilus Biotechnology news We have not published a story on Nautilus Biotechnology yet. When there is news, it will appear here. ## Nautilus Biotechnology at a glance - **Ticker**: NAUT - **Listing**: NASDAQ - **Country**: United States - **Cash, Sep 30, 2026**: $86.6 million ### Related companies - [Virax Biolabs Group](https://aibio.space/companies/virax-biolabs/) NASDAQ: VRAX - [Fortrea Holdings](https://aibio.space/companies/fortrea/) NASDAQ: FTRE - [CANNAPHARMARX, INC.](https://aibio.space/companies/cannapharmarx/) OTC: CPMD - [Intercure](https://aibio.space/companies/intercure/) NASDAQ: INCR - [CollPlant Biotechnologies](https://aibio.space/companies/collplant-biotechnologies/) NASDAQ: CLGN - [iRhythm Holdings](https://aibio.space/companies/irhythm/) NASDAQ: IRTC - [ProPhase Labs](https://aibio.space/companies/prophase-labs/) OTC: PRPH - [SMITH & NEPHEW](https://aibio.space/companies/smith-nephew/) NYSE: SNN ### Also on NASDAQ - [QT IMAGING HOLDINGS, INC.](https://aibio.space/companies/qt-imaging/) QTI - [SANUWAVE Health](https://aibio.space/companies/sanuwave-health/) SNWV - [Prothena Corporation](https://aibio.space/companies/prothena/) PRTA - [Kazia Therapeutics](https://aibio.space/companies/kazia-therapeutics/) KZIA - [SkinHealth Systems](https://aibio.space/companies/skinhealth-systems/) SKIN - [OKYO Pharma](https://aibio.space/companies/okyo-pharma/) OKYO ## Nautilus Biotechnology annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$41.1 million](https://www.sec.gov/Archives/edgar/data/1808805/000180880526000011/) | [$50.5 million](https://www.sec.gov/Archives/edgar/data/1808805/000180880526000011/) | | Net income (loss) | [-$59.0 million](https://www.sec.gov/Archives/edgar/data/1808805/000180880526000011/) | [-$70.8 million](https://www.sec.gov/Archives/edgar/data/1808805/000180880526000011/) | | Cash from operations | [-$50.7 million](https://www.sec.gov/Archives/edgar/data/1808805/000180880526000011/) | [-$59.1 million](https://www.sec.gov/Archives/edgar/data/1808805/000180880526000011/) | | Cash and equivalents | [$12.4 million](https://www.sec.gov/Archives/edgar/data/1808805/000180880526000052/) | [$27.6 million](https://www.sec.gov/Archives/edgar/data/1808805/000180880526000011/) | | Short-term investments | [$91.0 million](https://www.sec.gov/Archives/edgar/data/1808805/000180880526000052/) | [$102.2 million](https://www.sec.gov/Archives/edgar/data/1808805/000180880526000011/) | Latest balance sheet, Sep 30, 2026 (10-Q): cash and equivalents $10.5 million, plus short-term investments of $76.1 million, $86.6 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Nautilus Biotechnology What is the ticker symbol of Nautilus Biotechnology? Nautilus Biotechnology, Inc. trades under the ticker NAUT on NASDAQ. Where is Nautilus Biotechnology listed? Nautilus Biotechnology, Inc. is listed on NASDAQ. Which country or territory is Nautilus Biotechnology listed under? Our directory records Nautilus Biotechnology, Inc. under United States. Does aibio.space cover Nautilus Biotechnology? aibio.space lists Nautilus Biotechnology, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Is Nautilus Biotechnology profitable? Nautilus Biotechnology, Inc. reported a net loss of $59.0 million for the fiscal year ended Dec 31, 2025, and used $50.7 million of cash in operations, per its annual report to the SEC. How much does Nautilus Biotechnology spend on research and development? $41.1 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Nautilus Biotechnology have? $86.6 million in cash and short-term investments at Sep 30, 2026, per its 10-Q. ## Investor discussion: Nautilus Biotechnology Members talk about Nautilus Biotechnology (NAUT). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Nautilus Biotechnology, newest first. Each line links the filing it comes from. 1. 2026-09-11 Financings Reported a financing. SEC Form 8-K (Items 1.01,1.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1808805/000180880526000041/naut-20260911.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:NAUT on TradingView](https://www.tradingview.com/symbols/NASDAQ-NAUT/). ## Listing details Nautilus Biotechnology, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NAUT, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Nautilus Biotechnology, Inc. - **Ticker**: NAUT - **Listing**: NASDAQ - **Country or territory**: United States Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/nautilus-biotechnology/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Nautilus Biotechnology (NAUT) stock and investor profile", 2026-10-31, https://aibio.space/companies/nautilus-biotechnology/